Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693862 | 1.00 | CCKBR (0.51) | CCKBRKDM4EALDH1A1TDP1ALOX5AP | |
| SCHEMBL4690394 | 1.00 | CCKBR (0.51) | CCKBRKDM4EALDH1A1TDP1ALOX5AP | |
| SCHEMBL4690393 | 0.86 | CCKBR (0.50) | CCKBRKDM4EALDH1A1ALOX5APFEN1 | |
| SCHEMBL4693858 | 0.86 | CCKBR (0.50) | CCKBRKDM4EALDH1A1ALOX5APFEN1 | |
| SCHEMBL4494740 | 0.86 | CCKBR (0.50) | CCKBRKDM4EALDH1A1ALOX5APFEN1 | |
| SCHEMBL4505084 | 0.85 | ALOX5AP (0.46) | CCKBRALOX5APFEN1HCRTR1HCRTR2 | |
| SCHEMBL4693808 | 0.85 | ALOX5AP (0.46) | CCKBRALOX5APFEN1HCRTR1HCRTR2 | |
| SCHEMBL4692965 | 0.85 | ALOX5AP (0.46) | CCKBRALOX5APFEN1HCRTR1HCRTR2 | |
| SCHEMBL4693148 | 0.85 | ALOX5AP (0.46) | CCKBRALOX5APFEN1HCRTR1HCRTR2 | |
| SCHEMBL4510279 | 0.85 | ALOX5AP (0.46) | CCKBRALOX5APFEN1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | claimed |
| US-7304051-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | claimed |
| EP-1651621-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | claimed |
| WO-2005016896-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | claimed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | claimed |
| US-7563895-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | ALLISON BRETT D | 2008-03-27 | — | — | US | disclosed |
| US-7304051-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7288651-B2 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| EP-1651622-B1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1651621-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651622-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| US-20050043310-A1 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005016897-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016896-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | CCKBR 2/4885KDM4E 3167/4885ALDH1A1 4604/4885 |
| US-20050043310-A1 | Preparation of quinoxaline compounds | CCKAR, CCKBR, GIPR | CCKBR 2/4885KDM4E 3167/4885ALDH1A1 4604/4885 |
| US-20050038032-A1 | Quinoxaline compounds | CCKAR, CCKBR, GIPR | CCKBR 2/4885KDM4E 3681/4885ALDH1A1 4427/4885 |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | CCKBR 2/4885KDM4E 3681/4885ALDH1A1 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.